Capricor Therapeutics
CAPR
33 hedge funds and large institutions have $4.32M invested in Capricor Therapeutics in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
623% more capital invested
Capital invested by funds: $598K → $4.32M (+$3.73M)
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
83% more funds holding
Funds holding: 18 → 33 (+15)
0.99% more ownership
Funds ownership: 5.61% → 6.6% (+0.99%)
9% less call options, than puts
Call options by funds: $249K | Put options by funds: $274K
Top Buyers
| 1 |
Northern Trust
Chicago,
Illinois
|
+$647K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$518K |
| 3 |
Renaissance Technologies
New York
|
+$415K |
| 4 |
Two Sigma Investments
New York
|
+$189K |
| 5 |
Goldman Sachs
New York
|
+$169K |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$322K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.91K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.03K |
CAPR Hedge Fund Activity: Q2 2020 in Review
33 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2020, worth a combined $4.32M — up 623% from $598K a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CAPR positions and 3 closed out — a net gain of 15 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $647K. The largest seller was Armistice Capital, exiting entirely with an estimated $322K sold.
- 33 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2020, up from 18 in Q1 2020.
- Funds reported $4.32M of Capricor Therapeutics stock for Q2 2020, up 623% quarter-over-quarter.
- 18 funds opened new Capricor Therapeutics positions in Q2 2020 and 3 closed out, a net change of +15 holders.
- The largest Capricor Therapeutics buyer in Q2 2020 was Northern Trust, an estimated $647K added.
- The largest Capricor Therapeutics seller in Q2 2020 was Armistice Capital, an estimated $322K sold.
Based on aggregated 13F filings for Q2 2020.